tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

NTLA Stock Latest News

Intellia ATTR, HAE studies progressing as planned, says JPMorgan
The FlyIntellia ATTR, HAE studies progressing as planned, says JPMorgan
4d ago
NTLA
Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer
PremiumThe Fly
Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer
4d ago
NTLA
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
PremiumThe Fly
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
7d ago
NTLA
Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI
PremiumThe Fly
Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI
7d ago
WVE
NTLA
Intellia Therapeutics Restructures to Focus on Late-Stage Programs
PremiumCompany Announcements
Intellia Therapeutics Restructures to Focus on Late-Stage Programs
7d ago
8K
NTLA
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo
PremiumThe FlyIntellia Therapeutics price target lowered to $60 from $70 at Wells Fargo
7d ago
NTLA
Intellia Therapeutics announces net workforce reduction of 27% in 2025
Premium
The Fly
Intellia Therapeutics announces net workforce reduction of 27% in 2025
8d ago
NTLA
Intellia Therapeutics announces retirement of CSO Laura Sepp-Lorenzino
Premium
The Fly
Intellia Therapeutics announces retirement of CSO Laura Sepp-Lorenzino
8d ago
NTLA
Intellia Therapeutics: Phase 3 HAELO study to complete enrollment in 2H25
PremiumThe Fly
Intellia Therapeutics: Phase 3 HAELO study to complete enrollment in 2H25
8d ago
NTLA
Intellia Therapeutics price target lowered to $47 from $54 at RBC Capital
PremiumThe Fly
Intellia Therapeutics price target lowered to $47 from $54 at RBC Capital
10d ago
NTLA
Intellia Therapeutics price target lowered to $50 from $58 at BofA
PremiumThe Fly
Intellia Therapeutics price target lowered to $50 from $58 at BofA
10d ago
NTLA
Intellia Therapeutics reports inducement grants under Nasdaq listing rule
PremiumThe Fly
Intellia Therapeutics reports inducement grants under Nasdaq listing rule
11d ago
NTLA
Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today
PremiumThe FlyCathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today
1M ago
NTLA
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
BBIO
CABA
Intellia announces FDA granted RMAT designation to nexiguran ziclumeran
Premium
The Fly
Intellia announces FDA granted RMAT designation to nexiguran ziclumeran
2M ago
NTLA
REGN
Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today
PremiumThe Fly
Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today
2M ago
NTLA
Intellia Therapeutics Announces Promising CRISPR Therapy Results
PremiumCompany Announcements
Intellia Therapeutics Announces Promising CRISPR Therapy Results
2M ago
8K
NTLA
Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
PremiumThe Fly
Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
2M ago
NTLA
Intellia Therapeutics price target raised to $91 from $88 at Chardan
PremiumThe Fly
Intellia Therapeutics price target raised to $91 from $88 at Chardan
2M ago
NTLA
Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer
PremiumThe FlyIntellia Therapeutics price target lowered to $60 from $70 at Oppenheimer
2M ago
NTLA
Intellia Therapeutics price target lowered to $55 from $76 at Barclays
Premium
The Fly
Intellia Therapeutics price target lowered to $55 from $76 at Barclays
2M ago
NTLA
Intellia Therapeutics Reports Q3 2024 Financial Progress
Premium
Company Announcements
Intellia Therapeutics Reports Q3 2024 Financial Progress
2M ago
NTLA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >